Ifosfamide

Generic Name: Ifosfamide

Brand Names: Ifex

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 3778-73-2

Unique Ingredient Identifier: UM20QQM95Y

Background: Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.

Indication: Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indi...

Associated Conditions: Bladder Cancer, Cervical Cancer, Ewing's Sarcoma, Head And Neck Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma (NHL), Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Testicular Germ Cell Cancer, Thymoma

Associated Therapies: -

Clinical Trials

Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma

Phase 3

Conditions: Sarcoma

Interventions: Biological: dactinomycin
Drug: doxorubicin hydrochloride
Drug: busulfan
Drug: etoposide
Drug: ifosfamide
Drug: vincristine sulfate
Procedure: conventional surgery
Drug: melphalan
Radiation: radiation therapy
Procedure: autologous hematopoietic stem cell transplantation

First Posted Date: 2003-01-27

Last Posted Date: 2014-06-24

Lead Sponsor: University of Leicester

Target Recruit Count: 1200

Registration Number: NCT00020566

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States
🇺🇸
West Virginia University Health Sciences Center - Charleston, Charleston, West Virginia, United States

and more 100 locations

Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Drug: ifosfamide
Drug: vinorelbine tartrate

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-26

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 66

Registration Number: NCT00006760

Locations: 🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States
🇺🇸
Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States

and more 111 locations

Combination Chemotherapy Plus Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00002697

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma

Phase 3

Completed

Conditions: Ovarian Cancer
Kidney Cancer
Pheochromocytoma
Endometrial Cancer
Sarcoma

First Posted Date: 2003-01-27

Last Posted Date: 2014-08-08

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 350

Registration Number: NCT00002641

Locations: 🇦🇹
Karl-Franzens-University Graz, Graz, Austria
🇧🇪
Hopital Universitaire Erasme, Brussels, Belgium
🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium

and more 42 locations

Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2010-06-11

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 36

Registration Number: NCT00006260

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2023-12-27

Lead Sponsor: University of Nebraska

Registration Number: NCT00007865

Locations: 🇺🇸
University of Nebraska Medical Center, Eppley Cancer Center, Omaha, Nebraska, United States

High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer

Phase 1

Completed

Conditions: Cancer

Interventions: Biological: filgrastim
Drug: carboplatin
Drug: cisplatin
Drug: cyclophosphamide
Drug: etoposide
Drug: ifosfamide
Drug: mesna
Drug: paclitaxel
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-01-27

Last Posted Date: 2015-08-26

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 33

Registration Number: NCT00002854

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors

Phase 2

Completed

Conditions: Childhood Germ Cell Tumor
Brain Tumor
Central Nervous System Tumors

Interventions: Drug: carboplatin
Drug: etoposide
Drug: ifosfamide
Drug: thiotepa
Procedure: adjuvant therapy
Procedure: conventional surgery
Procedure: neoadjuvant therapy
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2018-02-14

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 104

Registration Number: NCT00047320

Locations: 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
Nemours Children's Clinic, Jacksonville, Florida, United States

and more 102 locations

Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Drug: carboplatin
Drug: carmustine
Drug: cyclophosphamide
Drug: cytarabine
Drug: etoposide
Drug: ifosfamide
Drug: melphalan
Procedure: bone marrow ablation with stem cell support
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2016-01-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 118

Registration Number: NCT00003631

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Liposomal Doxorubicin Plus Ifosfamide in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma

Phase 1

Completed

Conditions: Sarcoma

First Posted Date: 2003-01-27

Last Posted Date: 2012-09-24

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 28

Registration Number: NCT00030784

Locations: 🇩🇰
Aarhus University Hospital - Aarhus Sygehus - Norrebrogade, Aarhus, Denmark
🇩🇪
Robert Roessle Comprehensive Cancer Center at University of Berlin - Charite Campus Buch, Berlin, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy